Class information for:
Level 1: MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
693 3091 38.1 77%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
605 13295 MULTIPLE MYELOMA//THALIDOMIDE//MYELOMA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 MULTIPLE MYELOMA Author keyword 269 19% 41% 1277
2 LENALIDOMIDE Author keyword 99 33% 8% 248
3 BORTEZOMIB Author keyword 96 24% 11% 355
4 THALIDOMIDE Author keyword 76 20% 11% 335
5 MYELOMA UNIT Address 56 62% 2% 58
6 MYELOMA Author keyword 53 17% 9% 292
7 AZIENDA OSPED S GIOVANNI BATTISTA Address 28 58% 1% 32
8 SERAGNOLI HEMATOL Address 20 67% 1% 18
9 GRAFT VERSUS MYELOMA Author keyword 17 68% 0% 15
10 MYELOMA THER Y Address 15 20% 2% 69

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class		 LCSH search Wikipedia search
1 MULTIPLE MYELOMA 269 19% 41% 1277 Search MULTIPLE+MYELOMA Search MULTIPLE+MYELOMA
2 LENALIDOMIDE 99 33% 8% 248 Search LENALIDOMIDE Search LENALIDOMIDE
3 BORTEZOMIB 96 24% 11% 355 Search BORTEZOMIB Search BORTEZOMIB
4 THALIDOMIDE 76 20% 11% 335 Search THALIDOMIDE Search THALIDOMIDE
5 MYELOMA 53 17% 9% 292 Search MYELOMA Search MYELOMA
6 GRAFT VERSUS MYELOMA 17 68% 0% 15 Search GRAFT+VERSUS+MYELOMA Search GRAFT+VERSUS+MYELOMA
7 NOVEL AGENTS 15 32% 1% 39 Search NOVEL+AGENTS Search NOVEL+AGENTS
8 MELPHALAN 13 14% 3% 92 Search MELPHALAN Search MELPHALAN
9 ELOTUZUMAB 12 75% 0% 9 Search ELOTUZUMAB Search ELOTUZUMAB
10 RELAPSED REFRACTORY MULTIPLE MYELOMA 12 75% 0% 9 Search RELAPSED+REFRACTORY+MULTIPLE+MYELOMA Search RELAPSED+REFRACTORY+MULTIPLE+MYELOMA

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NEWLY DIAGNOSED MYELOMA 322 78% 7% 215
2 LENALIDOMIDE PLUS DEXAMETHASONE 259 67% 8% 236
3 THALIDOMIDE PLUS DEXAMETHASONE 212 80% 4% 132
4 PREDNISONE PLUS THALIDOMIDE 138 85% 2% 73
5 PLUS DEXAMETHASONE 117 40% 7% 226
6 MELPHALAN PREDNISONE 101 78% 2% 67
7 REFRACTORY MYELOMA 99 54% 4% 129
8 THALIDOMIDE 96 20% 14% 420
9 BORTEZOMIB 92 23% 11% 344
10 MELPHALAN 82 21% 11% 346

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLINICAL LYMPHOMA & MYELOMA 4 11% 1% 34

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
MEDICAL PROGRESS Multiple Myeloma 2011 407 80 69%
Current treatment landscape for relapsed and/or refractory multiple myeloma 2015 4 82 84%
Drug therapy: Multiple myeloma 2004 729 84 62%
Multiple myeloma 2008 292 55 75%
Multiple myeloma 2009 258 113 61%
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) 2014 37 100 42%
Proteasome inhibitors in multiple myeloma: 10 years later 2012 114 69 64%
Association of response endpoints with survival outcomes in multiple myeloma 2014 10 104 90%
Treatment of multiple myeloma 2011 66 75 81%
Frontline therapy of multiple myeloma 2015 1 71 93%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MYELOMA UNIT 56 62% 1.9% 58
2 AZIENDA OSPED S GIOVANNI BATTISTA 28 58% 1.0% 32
3 SERAGNOLI HEMATOL 20 67% 0.6% 18
4 MYELOMA THER Y 15 20% 2.2% 69
5 AZIENDA OSPED UNIV AOU S GIOVANNI BATTISTA 11 100% 0.2% 6
6 EMATOL 10 11% 2.8% 86
7 EXCELLENCE LYMPHOMA MYELOMA 8 70% 0.2% 7
8 IST EMATOL SERAGNOLI 8 45% 0.5% 14
9 CLIN EMATOL 8 23% 1.0% 31
10 IBMCC USAL CSIC 7 53% 0.3% 10

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000211455 PLASMA CELL LEUKEMIA//PRIMARY PLASMA CELL LEUKEMIA//MMSET
2 0.0000137042 THALIDOMIDE//CC 5013//CC 4047
3 0.0000118649 MYELOMA BONE DISEASE//CAM DR//HEIM
4 0.0000104823 IMMUNOFIXATION ELECTROPHORESIS//FREE LIGHT CHAINS//SERUM FREE LIGHT CHAINS
5 0.0000101175 BORTEZOMIB//PROTEASOME INHIBITOR//PROTEASOME INHIBITORS
6 0.0000098831 LIGHT CHAIN DEPOSITION DISEASE//CRYSTAL STORING HISTIOCYTOSIS//HEAVY CHAIN DEPOSITION DISEASE
7 0.0000072196 PLASMACYTOMA//EXTRAMEDULLARY PLASMACYTOMA//SOLITARY PLASMACYTOMA
8 0.0000066726 BENDAMUSTINE//TREANDA//BENDAMUSTIN
9 0.0000058810 PLERIXAFOR//LARGE VOLUME LEUKAPHERESIS//STEM CELL MOBILIZATION
10 0.0000054649 TRANSPLANT RATES//EBMT ACT SURVEY OFF//OPERAT COMPUTAT FINANCE